NKL

Nippon Kayaku is a diversified Japanese chemical and pharmaceutical company with a significant presence in the oncology and biosimilar markets. The company's pharmaceutical division focuses on the development and commercialization of anti-cancer agents, including innovative drug delivery systems like polymeric micelles. Nippon Kayaku is also a leader in the Japanese biosimilar market, offering versions of major biologics such as trastuzumab and infliximab. Beyond oncology, the company provides treatments for inflammatory diseases and cardiovascular conditions. Their research and development efforts are centered on improving the efficacy and safety of existing therapies through advanced formulation technologies.